Photo of Christopher B. Capel

Christopher B. Capel

AA Contact Info

Amanda Diniz
Phone: 919.838.2063


Christopher Capel has extensive experience advising emerging and established companies, both privately and publicly held, in corporate, securities, and technology law matters. His practice emphasizes mergers and acquisitions, corporate finance (including public offerings and private placements of securities), intellectual property and technology licensing and protection, and public company reporting and compliance. Clients describe Chris as "a strategic thinker," who "brings a strong legal foundation to business situations" (Chambers USA). He also advises companies and their directors and officers on corporate governance matters and other general corporate and business law matters. These matters involve a variety of industries, including a focus on the pharmaceutical, biotech and other life sciences areas. Frequently, these matters involve international transactions.

Christopher also focuses on venture capital and private equity transactions, representing private equity firms, venture capital funds, and corporate investors, as well as venture capital-backed companies and start-ups. In addition, he regularly assists companies and investors with strategic alliances and collaborations, joint ventures, and other partnering arrangements.

Prior to Smith Anderson, Christopher practiced in New York City with a global law firm. He is licensed to practice law in North Carolina and New York. Before entering law practice, he was a corporate loan officer with Wachovia Bank. Christopher received his law degree from the University of North Carolina, where he graduated with honors and was on the Law Review.

  • American Bar Association
  • New York Bar Association
  • North Carolina Bar Association
    • Past Chair, Business Law Section
    • Past Chair, Business Organizations Committee, Business Law Section
    • Past Co-Chair, Legal Opinion Committee, Business Law Section
  • Wake County, NC Bar Association
  • North Carolina Biosciences Organization (NCBio), Board of Directors
    • Director, Executive Committee
    • Director, Audit Committee 
  • Licensing Executives Society, Research Triangle Chapter, Member 
  • North Carolina Arts in Action, Board of Directors 
  • Ruth Sheets Adult Day Care Center, Board of Directors
  • Edenton Street United Methodist Church, Board of Trustees
  • Alice Aycock Poe Center for Health Education, Past Director
  • ArtSpace, Inc., a non-profit visual arts center, Past Director and Past Chairman of the Board of Directors
  • Saint Mary's School, Board of Visitors, Past Member
  • Best Lawyers®, Biotechnology and Life Sciences Practice; Corporate Law; Mergers & Acquisitions; Securities / Capital Markets; Securities Regulation; Venture Capital (2006-2022)
  • Best Lawyers®, "Lawyer of the Year," Raleigh Securities Regulation (2020) and Securities/Capital Markets Law (2014, 2017, 2019) 
  • Business North Carolina Legal Elite, Business Law
  • Chambers USA: America’s Leading Lawyers for Business, Corporate/M&A (2006-2021)
  • North Carolina Super Lawyers (2006-2019)
  • "Highly Regarded," IFLR1000: The Guide to the World's Leading Financial Law Firms, M&A (2018-2021) 
  • Martindale-Hubbell: AV Preeminent Rated; Top Rated in Securities Law 
  • National Eagle Scout Association



  • Represented a Nasdaq-listed bank holding company in a public offering of subordinated notes for aggregate proceeds of $350 million.
  • Represented a Nasdaq-listed bank holding company in a public offering of depositary shares representing interests in preferred stock for aggregate proceeds of $345 million.
  • Advised a publicly traded, global tobacco company on its $50 billion merger with another major publicly traded tobacco company.
  • Advised a multinational Fortune 500 provider of product development and integrated healthcare services in its merger with a NYSE-listed global information and technology services company, creating a leading information and tech-enabled healthcare service provider. The equity market capitalization of the joined companies was more than $17.6 billion at closing.
  • Joint venture between our client, the world's largest public company provider of biopharmaceutical development services and commercial outsourcing services, and the world's leading public company provider of diagnostic information services, to form a global clinical trials laboratory services business with annual revenues of approximately $575 million.
  • Merger of our client, a publicly-traded developer of diagnostic tests, with one of the largest clinical laboratory companies in the U.S.
  • Private placement offering of securities by our client, a clinical-stage biotech company, to individual and institutional investors.
  • In-license of university-developed intellectual property by our client, a newly formed medical device company.
  • Formation and funding of specialty pharmaceutical company by our clients, a group of venture capital investors, and related in-license of pharmaceutical product rights from a global pharmaceutical company.
  • Collaboration/strategic alliance between our client, a global provider of biopharmaceutical development services and commercial outsourcing services, and a global, Japan-based pharmaceutical company for the development of pharmaceutical products on a risk-sharing basis.
  • Divestment by our client, a global pharmaceutical, vaccines and consumer health company, of pharmaceutical product rights to a specialty pharmaceutical company.
  • License by our client, a publicly-traded specialty pharmaceutical company, from another specialty pharmaceutical company of pharmaceutical intellectual property rights.
  • Venture capital financing transaction involving our client, an emerging technology company.
  • License and acquisition by our client, a global specialty pharmaceutical company, of pharmaceutical intellectual property from a global pharmaceutical company and related sub-licenses from other global pharmaceutical companies.
  • Supply and manufacturing contracts involving our client, a publicly-traded specialty pharmaceutical company, and out-sourced contract manufacturers for bulk product and finished product.

News & Publications


Bar & Court Admissions

  • North Carolina
  • New York


University of North Carolina, J.D., with honors, 1985

University of North Carolina, A.B., 1979


  • Federal Judicial Law Clerk to the Honorable Sam J. Ervin III, United States Court of Appeals, Fourth Circuit 
Lawyer Directory
Back to Page